Investment analysts at HC Wainwright boosted their FY2027 EPS estimates for shares of Oncolytics Biotech in a research report ...
Equities research analysts at Leede Financial boosted their FY2025 earnings per share (EPS) estimates for shares of ...
Oncolytics Biotech faces financial struggles and unclear pelareorep efficacy signals. Learn why ONCY stock's risks outweigh ...
Oncolytics Biotech (ONCY) has disclosed a new risk, in the Corporate Activity and Growth category. Oncolytics Biotech faces significant business ...
Oncolytics Biotech Inc. (ONCY) has been beaten down lately with too much selling pressure. While the stock has lost 9.3% over the past four weeks, there is light at the end of the tunnel as it is ...
Maxim lowered the firm’s price target on Oncolytics (ONCY) to $3 from $5 and keeps a Buy rating on the shares. The firm is adjusting its model ...
CNW/ -- (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today ...
RBC Capital lowered the firm’s price target on Oncolytics (ONCY) to C$5 from C$6 and keeps an Outperform rating on the shares.Optimize Your ...
USA News Group News Commentary – As cancer rates continue to climb worldwide, the push for innovative treatments has never ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results